2,851 results on '"Leukemia, T-Cell"'
Search Results
2. Observatory of Prolymphocytic Leukemia T (T-PLL)
3. CD4CAR for CD4+ Leukemia and Lymphoma
4. Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (DARATALL-VHR)
5. Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
6. Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
7. Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) (CASEY)
8. A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low
9. Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ('EPOCH') for Adult T-Cell Leukemia-Lymphoma (ATL)
10. Novel Therapeutic Approach for Human T-cell Malignancies
11. Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
12. Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (BAH246)
13. 9-ING-41 in Patients With Advanced Cancers
14. Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
15. Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia
16. Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
17. Venetoclax Based Regimen for R/R T-ALL
18. KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
19. A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
20. Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
21. Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
22. Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
23. Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
24. CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
25. Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
26. Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
27. Ipilimumab and Local Radiation for Selected Solid Tumors
28. Precision Exercise in Children With Malignant Hemopathies (SportTherapy)
29. A Registry for People With T-cell Lymphoma
30. Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
31. Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
32. Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
33. Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
34. Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
35. RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
36. Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
37. Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
38. A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
39. Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
40. Ruxolitinib for Adult T-Cell Leukemia
41. Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
42. CAR-T Cells in the Treatment of Malignant Hematological Tumors
43. Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
44. Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma
45. LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma
46. LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
47. Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
48. Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
49. Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
50. Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.